The HINT1 Knockout Jurkat Polyclonal Cells product provides a CRISPR/Cas9-mediated polyclonal knockout cell population derived from the Jurkat human T-lymphocyte line, designed to disrupt the endogenous HINT1 gene locus. This loss-of-function model enables investigation of HINT1-dependent molecular mechanisms in a well-characterized T-cell leukemia background. The polyclonal format represents a heterogeneous knockout population, suitable for functional analyses without clonal selection, offering a robust system for pathway interrogation and target validation.
Jurkat cells are an immortalized human T lymphocyte cell line originally established from an acute T-cell leukemia patient (Jurkat E6-1 clone). They serve as a widely used model for T-cell receptor (TCR) signaling, interleukin-2 production, and apoptosis studies. The Jurkat background provides a physiologically relevant context for studying lymphocyte biology, signal transduction, and leukemogenic processes, making it an ideal host for examining the tumor-suppressive and transcriptional regulatory roles of HINT1.
HINT1 encodes a histidine triad nucleotide-binding protein 1 that hydrolyzes purine nucleotide phosphoramidates and acts as a tumor suppressor by physically interacting with transcription factors such as MITF and USP2, thereby modulating gene expression programs controlling cell cycle and apoptosis. Activated downstream of p53 and genotoxic stress, HINT1 loss disrupts complexes with MITF, PKC, casein kinase 2, and TAF1, altering the regulation of MITF, cyclin D1, Bax, and Bcl-2 family members. This impacts ??-catenin/TCF/LEF-mediated transcription, MDM2-p53 feedback, and caspase-3 activation.
In Jurkat T cells, HINT1 knockout is predicted to perturb pro-survival and pro-apoptotic signaling, potentially enhancing proliferation and altering TCR-driven responses. Disrupting HINT1??s interaction with MITF and USP2 may dysregulate cell cycle and apoptosis gene transcription, offering a model for tumor suppressor evasion in leukemia. This polyclonal population enables examination of immediate signaling (e.g., phospho-ERK, phospho-AKT) and long-term transcriptional outputs, facilitating dissection of HINT1??s role in T-cell transformation and therapy resistance.
Researchers can employ this knockout model in diverse assays including Western blotting to confirm HINT1 ablation, co-immunoprecipitation to assess altered protein complexes, luciferase reporter assays for TCF/LEF or p53 activity, flow cytometry with Annexin V/PI for apoptosis quantification, RT-qPCR for target gene expression, phospho-signaling analysis, and cell viability (MTT/ATP) measurements. These applications support investigations into T-cell leukemia biology, tumor suppressor mechanisms, transcriptional regulation by MITF, and immuno-oncology target validation. For further information, please contact Ascent Research.
